Business, energy, technology, markets and global industry news from Business News Today

YARTEMLEA

PharmaDeviceNews YARTEMLEA
Representative image: Omeros Corporation faces a crucial European regulatory test after the CHMP rejected narsoplimab for TA-TMA, raising fresh questions over clinical evidence, trial design and the therapy’s path to approval.
Pharma & Biotech

Omeros’ TA-TMA therapy hits European hurdle as regulators question treatment effect

Omeros faces a CHMP refusal for narsoplimab in TA-TMA. Read what the EU re-examination means for evidence, access and launch plans.

Read More
Representative image illustrating transplant‑associated thrombotic microangiopathy, a life‑threatening complication after hematopoietic stem cell transplantation that is now the focus of new FDA‑approved treatment advances by Omeros Corporation.
Pharma & Biotech

Omeros secures FDA approval for YARTEMLEA, the first therapy for transplant-associated TA-TMA

FDA approves YARTEMLEA for TA-TMA. Find out how Omeros’ new drug could change transplant care for children and adults alike.

Read More